AstraZeneca - GBPAstraZeneca - GBPAstraZeneca - GBP

AstraZeneca - GBP

No trades
See on Supercharts

Key facts today

AstraZeneca's Calquence, a BTK inhibitor launched in 2017, competes with BeiGene's Brukinsa from 2019. The BTK inhibitor market is expected to expand significantly.
Analyze the impactAnalyze the impact

See all ideas